The findings demonstrate that overexpression of USP28 correlates with a better survival in patients with invasiveductalbreastcarcinoma.
2
We examined CTCF protein expression in 18 invasiveductalbreastcarcinomas using immunohistochemistry.
3
We have examined 301 invasiveductalbreastcarcinomas by this method.
1
Three females presented with invasiveductalcarcinomaofthebreast after treatment for Hodgkin's disease.
2
These results also suggest the prognostic value of pAkt and its importance in the prediction of therapeutic response in invasiveductalcarcinomaofthebreast.
3
Sixteen patients with invasiveductalcarcinomaofthebreast were prospectively included and underwent both, contrast-enhanced breast MRI and (1)H MRS examination of the breast.
4
Conclusions: Histopathologic grading and flow cytometric determination of SPF appear to provide additive prognostic information for patients with early invasiveductalcarcinomasofthebreast.
1
Histological analysis indicated infiltratingductalcarcinoma in all cases.
2
We report on a rare distinctive variant of infiltratingductalcarcinoma characterized by sebaceous differentiation of tumor cells.
3
Fourteen patients who underwent scintimammography and subsequent surgical excisional biopsy that revealed infiltratingductalcarcinoma were enrolled in this study.
1
The tumor showed features of poorly differentiated invasiveductalcarcinoma of clear-cell phenotype.
2
Available data suggest improved outcome for papillary carcinoma as compared to invasiveductalcarcinoma.
3
Histological findings for the lymph node indicated a metastasis of the invasiveductalcarcinoma.
4
Three females presented with invasiveductalcarcinoma of the breast after treatment for Hodgkin's disease.
5
Histopathology confirmed a bifocal invasiveductalcarcinoma.
1
The aim of this study was to assess the relationship between the degree of MIBI tumor uptake and cadherin expression in infiltratingductalbreastcarcinoma.
Uso de ductal adenocarcinoma en inglés
1
Hypoxia contributes to the aggressive and treatment-resistant phenotype of pancreatic ductaladenocarcinoma.
2
Conclusions: This paper emphasizes the grim prognosis of pancreatic ductaladenocarcinoma.
3
Purpose: To evaluate imaging findings of diffuse pancreatic ductaladenocarcinoma.
4
HG-PanIN mutation profiles were compared with those of their associated invasive pancreatic ductaladenocarcinoma.
5
Methods: We prospectively collected data on the families of patients presenting with pancreatic ductaladenocarcinoma.
6
A literature search revealed only 3 prior reports of primary ductaladenocarcinoma of the lacrimal gland.
7
To test our hypothesis, we have used Panc1 cells, which is a pancreatic ductaladenocarcinoma cell type.
8
Maspin may be helpful in differentiating ductaladenocarcinoma from chronic pancreatitis, once squamous metaplasia is ruled out.
9
Assessment of PTEN expression may be used as a prognostic marker for patients with resected pancreatic ductaladenocarcinoma.
10
The identity of the cell of origin for pancreatic ductaladenocarcinoma (PDAC) has long been debated.
11
Pancreatic ductaladenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens.
12
We aimed to identify stress-associated molecular responses to PL treatment in pancreatic ductaladenocarcinoma (PDAC) cells.
13
Pancreatic ductaladenocarcinoma (PDAC) is an aggressive malignancy characterized by extensive local invasion and systemic spread.
14
Pancreatic ductaladenocarcinoma (PDA) remains one of the most aggressive tumors with a low rate of survival.
15
Pancreatic ductaladenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality.
16
Pancreatic ductaladenocarcinoma (PDAC) is one of the leading causes of cancer death in the Western world.